Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 17/20 | 0.42 |
| ▸ | JAK1 | P23458 | 16/20 | 0.42 |
| ▸ | JAK3 | P52333 | 16/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16795294 | 0.85 | DYRK1A (0.50) | DYRK1AJAK2JAK1JAK3CCNK | |
| SCHEMBL18302116 | 0.82 | JAK2 (0.54) | JAK2JAK1JAK3 | |
| SCHEMBL2342714 | 0.82 | DYRK1A (0.47) | DYRK1AJAK2JAK1JAK3CCNK | |
| SCHEMBL16795169 | 0.82 | DYRK1A (0.47) | DYRK1AJAK2JAK1JAK3CCNK | |
| SCHEMBL18302112 | 0.81 | DYRK1A (0.49) | DYRK1AJAK2JAK1JAK3CCNK | |
| SCHEMBL30060574 | 0.81 | CYP11B1 (0.33) | JAK2JAK1JAK3 | |
| SCHEMBL16795132 | 0.78 | JAK2 (0.40) | DYRK1AJAK2JAK1JAK3EPHB3 | |
| SCHEMBL18302420 | 0.78 | JAK2 (0.70) | DYRK1AJAK2JAK1JAK3 | |
| SCHEMBL20240136 | 0.78 | JAK2 (0.70) | DYRK1AJAK2JAK1JAK3 | |
| SCHEMBL16795293 | 0.77 | CCNT1 (0.61) | JAK2JAK1JAK3CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2020-09-01 | — | — | US | disclosed |
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2018-06-14 | — | — | US | disclosed |
| EP-3307272-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198663-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2016-12-15 | — | — | WO | disclosed |
| WO-2015086693-A1 | PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK3, JAK1 | DYRK1A 443/4885JAK2 1/4885JAK1 3/4885 |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | JAK2, JAK3, JAK1 | DYRK1A 443/4885JAK2 1/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.